These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15665796)

  • 21. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.
    Moreno R; Fernández C; Hernández R; Alfonso F; Angiolillo DJ; Sabaté M; Escaned J; Bañuelos C; Fernández-Ortiz A; Macaya C
    J Am Coll Cardiol; 2005 Mar; 45(6):954-9. PubMed ID: 15766835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
    Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
    J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents.
    Elezi S; Dibra A; Mehilli J; Pache J; Wessely R; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Oct; 48(7):1304-9. PubMed ID: 17010786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-eluting stents versus bare metal stents following rotational atherectomy for heavily calcified coronary lesions: late angiographic and clinical follow-up results.
    Khattab AA; Otto A; Hochadel M; Toelg R; Geist V; Richardt G
    J Interv Cardiol; 2007 Apr; 20(2):100-6. PubMed ID: 17391217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study.
    Suttorp MJ; Laarman GJ;
    Am Heart J; 2007 Sep; 154(3):432-5. PubMed ID: 17719285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus-eluting stents. (The results of the five-year use for the treatment of coronary artery disease).
    Krylov AL
    Angiol Sosud Khir; 2006; 12(4):71-82. PubMed ID: 17679960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restenosis treatment in the drug-eluting stent era.
    Presbitero P; Boccuzzi G
    Ital Heart J; 2005 Jun; 6(6):514-21. PubMed ID: 16008157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The paclitaxel-eluting stent in percutaneous coronary intervention: part I: background and clinical comparison to bare metal stents.
    Gruchalla KJ; Nawarskas JJ
    Cardiol Rev; 2006; 14(2):88-98. PubMed ID: 16493246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
    Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
    J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
    Bavry AA; Kumbhani DJ; Helton TJ; Bhatt DL
    J Am Coll Cardiol; 2005 Mar; 45(6):941-6. PubMed ID: 15766833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial.
    Pache J; Dibra A; Mehilli J; Dirschinger J; Schömig A; Kastrati A
    Eur Heart J; 2005 Jul; 26(13):1262-8. PubMed ID: 15737962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus-eluting stents for the treatment of atherosclerotic ostial lesions.
    Aziz S; Ramsdale DR
    J Invasive Cardiol; 2005 Jan; 17(1):13. PubMed ID: 15640532
    [No Abstract]   [Full Text] [Related]  

  • 37. The sirolimus coated stent: will the Achilles heel of interventional cardiology finally be cured?
    Beyar R; Roguin A
    Eur Heart J; 2001 Nov; 22(22):2054-7. PubMed ID: 11686663
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug-eluting stents for the prevention of restenosis: Standing the test of time.
    Carter AJ
    Catheter Cardiovasc Interv; 2002 Sep; 57(1):69-71. PubMed ID: 12203932
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues.
    Hodgson JM; Bottner RK; Klein LW; Walpole HT; Cohen DJ; Cutlip DE; Fenninger RB; Firth BG; Greenberg D; Kalisky I; Meskan T; Powell W; Stone GW; Zito JP; Clark MA
    Catheter Cardiovasc Interv; 2004 May; 62(1):1-17. PubMed ID: 15103593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complex coronary intervention in the drug-eluting stent era. Introduction.
    Kereiakes DJ
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S1-2. PubMed ID: 15665792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.